LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
Graphite Bio Declares Dividend In Connection with Proposed Merger with Lenz
Tr1x launched from stealth Wednesday with $75 million to tackle graft-versus-host disease in addition to inflammatory and autoimmune conditions.
SAN DIEGO — After Graphite Bio’s implosion, Matthew Porteus wants to do things differently.
Kamau Therapeutics has emerged from stealth mode after inking a deal with Graphite Bio for its genome editing assets. Kamau’s debut comes less than a month after Graphite entered a reverse merger deal with Lenz Therapeutics to form a new combined company.
Nine months after throwing in the towel on its gene editing program for sickle cell disease, Graphite Bio said it has found a reverse merger partner to take its spot on the Nasdaq.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensure an orderly transition.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and to initiate a process to explore a range of strategic alternatives.
Beam Therapeutics CEO John Evans is well aware that sickle cell is a crowded area when it comes to gene therapy, but as data roll in, each candidate is beginning to differentiate itself.
Graphite has hit a major roadblock as an adverse event caused the gene-therapy-focused biotech to pause its lead program.